These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8787932)

  • 1. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM.
    Marks SJ; Moore NR; Clark ML; Strauss BJ; Hockaday TD
    Obes Res; 1996 Jan; 4(1):1-7. PubMed ID: 8787932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic indices in relation to body composition changes during weight loss on Dexfenfluramine in obese women from two South African ethnic groups.
    van der Merwe MT; Wing JR; Celgow LH; Gray IP; Lönn L; Joffe BI; Lönnroth PN
    Int J Obes Relat Metab Disord; 1996 Aug; 20(8):768-76. PubMed ID: 8856402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic effects of preferential reduction of visceral adipose tissue in abdominally obese men.
    Marks SJ; Chin S; Strauss BJ
    Int J Obes Relat Metab Disord; 1998 Sep; 22(9):893-8. PubMed ID: 9756248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM.
    Marks SJ; Moore NR; Ryley NG; Clark ML; Pointon JJ; Strauss BJ; Hockaday TD
    Int J Obes Relat Metab Disord; 1997 Apr; 21(4):274-9. PubMed ID: 9130023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors.
    Swinburn BA; Carmichael HE; Wilson MR
    Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Enzi G
    Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM.
    Banerji MA; Buckley MC; Chaiken RL; Gordon D; Lebovitz HE; Kral JG
    Int J Obes Relat Metab Disord; 1995 Dec; 19(12):846-50. PubMed ID: 8963350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of genetic prediabetic south Indian subjects. Importance of hyperinsulinemia and beta-cell dysfunction.
    Snehalatha C; Ramachandran A; Satyavani K; Latha E; Viswanathan V
    Diabetes Care; 1998 Jan; 21(1):76-9. PubMed ID: 9538973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women.
    Flechtner-Mors M; Ditschuneit HH; Yip I; Adler G
    Am J Clin Nutr; 1998 Apr; 67(4):611-5. PubMed ID: 9537607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
    Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
    Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?
    Brochu M; Tchernof A; Dionne IJ; Sites CK; Eltabbakh GH; Sims EA; Poehlman ET
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1020-5. PubMed ID: 11238480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity.
    Oleandri SE; Maccario M; Rossetto R; Procopio M; Grottoli S; Avogadri E; Gauna C; Ganzaroli C; Ghigo E
    J Endocrinol Invest; 1999 Feb; 22(2):134-40. PubMed ID: 10195381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction.
    Van Gaal L
    Verh K Acad Geneeskd Belg; 1989; 51(1):47-80. PubMed ID: 2800685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables and their inter-relationships.
    Zamboni M; Armellini F; Milani MP; De Marchi M; Todesco T; Robbi R; Bergamo-Andreis IA; Bosello O
    Int J Obes Relat Metab Disord; 1992 Jul; 16(7):495-504. PubMed ID: 1323546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between ultrasound measures of abdominal fat distribution and indices of glucose metabolism in a population at high risk of type 2 diabetes: the ADDITION-PRO study.
    Philipsen A; Jørgensen ME; Vistisen D; Sandbaek A; Almdal TP; Christiansen JS; Lauritzen T; Witte DR
    PLoS One; 2015; 10(4):e0123062. PubMed ID: 25849815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
    Ditschuneit HH; Flechtner-Mors M; Adler G
    J Cardiovasc Risk; 1996 Aug; 3(4):397-403. PubMed ID: 8946272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity.
    Park HS; Lee K
    Diabet Med; 2005 Mar; 22(3):266-72. PubMed ID: 15717873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.